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Abstract
Background: Listening to “patient voices” in terms of symptoms, emotional status and experiences with care, is
crucial for patient empowerment in clinical practice. Despite convincing evidence that routine patient reported
outcomes and experience measurements (PRMs) with rapid feed-back to oncologists can improve symptom
control, patient well-being and cost effectiveness, PRMs are not commonly used in cancer care, due to barriers at
various level. Part of these barriers may be overcome through electronic PRMs collection (ePRMs) integrated with
the electronic medical record (EMR). The PATIENT VOICES initiative is aimed at achieving a stepwise integration of
ePRMs assessment into routine cancer care. The feasibility project presented here is aimed at assessing the
knowledge, use and attitudes toward PRMs in a comprehensive cancer centre; developing and assessing feasibility
of a flexible system for ePRM assessment; identifying barriers to and developing strategies for implementation and
integration of ePRMs clinical practice.
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Methods: The project has been organized into four phases: a) pre-development; b) software development and
piloting; c) feasibility assessment; d) post-development. A convergent mixed method design, based on concurrent
quantitative and qualitative data collection will be applied. A web-survey on health care providers (HCPs),
qualitative studies on patients and HCPs (semi-structured interviews and focus groups) as well as longitudinal and
cross-sectional quantitative studies will be carried out. The quantitative studies will enroll 600 patients: 200
attending out-patient clinics (physical symptom assessement), 200 attending inpatient wards (psychological distress
assessment) and 200 patients followed by multidisciplinary teams (patient experience with care assessment). The
Edmonton symptom assessment scale, the Distress Thermometer, and a tool adapted from existing patient
reported experience with cancer care questionnaires, will be used in quantitative studies. A multi-disciplinary
stakeholder team including researchers, clinicians, health informatics professionals, health system administrators and
patients will be involved in the development of potentially effective implementation strategies in the post
development phase.
Discussion: The documentation of potential advantages and implementation barriers achieved within this
feasibility project, will serve as a starting point for future and more focused interventions aimed at achieving
effective ePRMs routine assessment in cancer care.
Trial registration: ClinicalTrials.gov (NCT03968718) May 30th, 2019.
Keywords: Patient participation, Patient reported outcome measures, Medical informatics, Implementation science,
Oncology
Background
The recognition of the patients’ perspective as crucial
in medical decision making, represents a major shift in
medicine during the last decades [1]. Listening to “pa-
tient voices” in terms of symptoms, function, emotional
status, satisfaction and experiences with treatment and
care received, is essential for the empowerment of both
patients and their caregivers to become more involved
in the care process. This is particularly true for cancer,
where people often face difficult decisions due to the
complexity of treatment choices, tied to the life-
threatening nature of the illness and to its emotional
consequences.
The assessment of the patient perception of his/her
health condition has been labelled differently, but the
terms “Quality of Life” introduced in the 1980s, and the
following “Health-related Quality of life”, were for long
the most frequently used. In 2006 the U.S. Food and
Drug Administration proposed to use the term PROs
(Patient Reported Outcomes), later extended into
PROMs (Patient Reported Outcomes Measures), to indi-
cate “any report of the status of a patient’s health condi-
tion that comes directly from the patient, without
interpretation of the patient’s response by a clinician or
anyone else” [2]. More recently the term PREMs (Patient
reported experience measures) has been introduced to
indicate patients’ perceptions of their experience of the
process of care, rather than outcome. PREMs can evalu-
ate objective experiences (i.e waiting time before ap-
pointment), observations of healthcare providers’
behaviour (i.e whether or not a patient was given a due
information) or satisfaction for the care received, the
latter being more influenced by patient expectations and
preferences [3, 4]. For sake of simplicity the terminology
“patient reported measures” (PRMs) will be used to
jointly indicate PROMs and PREMs in the present
paper.
PRMs were initially developed to be applied in clinical
research to assess efficacy and effectiveness of medical
interventions, but they can also be used in clinical prac-
tice to drive medical decisions. While the use of PRMs
in clinical research is fairly well established, systematic
assessment in clinical practice is not widely implemented
in routine care delivery [5–7] and may pose practical
challenges, like the burden for healthcare providers in
administering questionnaires before or during the med-
ical encounter or the difficulty in interpreting results.
Nonetheless, systematic symptom assessment in oncol-
ogy practice is considered one key element of effective
integration between oncology and palliative care [8] and
there is now convincing evidence that routine use of
PROM with rapid feed-back of results to health care
providers (HCP), can improve symptom control, patient
well-being, cost effectiveness as well as patient engage-
ment and survival [5, 9–12].
Engagement in health care is related to the involve-
ment of the patients, but also of caregivers, clinicians,
and other stakeholders (such as researchers, purchasers,
policy makers), recognising great relevance to multidis-
ciplinary collaboration [13]. In particular, patient en-
gagement can be defined as the promotion and support
of the active involvement and participation of patients,
recognizing them adequate decision-making role within
the health care process. Recent studies showed that
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patients with higher levels of engagement reported
better physical and psycho-social outcomes of care [14],
and that stakeholder engagement was critical for suc-
cessful implementation of PROMs in cancer care [15].
Advances in health information technology have pro-
moted the development of electronic tools for the collec-
tion of PROMs and PREMs through mobile devices
(ePRMs), a number of which are currently used in
oncology practice [16, 17]. Such systems may help in
overcoming some of the limitations mentioned above,
permit distant follow-up of patients who are not hospi-
talized, promote data sharing among care team members
and offer powerful opportunities for their integration
with patient data from other sources (i.e physicians
reported data from electronic medical record (EMR),
laboratory data, administrative and cost data).
It has recently been highlighted that successful inte-
gration of ePROMs would require overcoming not only
technological and reimbursement barriers but also oper-
ational ones like standardized methods for integrating
them into the clinical workflow [7]. In order to develop
effective integration plans, direct evidence on acceptabil-
ity and feasibility for patients and HCPs, are needed in
disease-specific patient populations and countries. Actu-
ally the full potential of EMR will not be achieved with-
out the inclusion and integration of PROMs within the
EMR itself [7, 18].
At present no standardized PRMs assessment is rou-
tinely performed at the Fondazione IRCCS Istituto
Nazionale Tumori of Milano (INT) and to the best of
our knowledge, no evidence has been published regard-
ing routine PROMs assessment in oncology practice in
Italy. The PATIENT VOICES project is aimed at achiev-
ing a stepwise integration of PRMs assessment into rou-
tine clinical cancer care in our Institute. The feasibility
project presented here is the first step in the implemen-
tation project. It has been organized into four subse-
quent phases as reported in Fig. 1:
1. pre-development
2. software development and piloting
3. feasibility assessment
4. post-development phase.
Specific aims and methods of each phase are reported
in the following paragraphs.
Aims and methods
This study protocol has been developed following a
convergent mixed method design, based on a concurrent
quantitative and qualitative data collection, followed by
separated analysis for each method with the aim to
obtain different but complementary data on the same
topic [19–21] thus gaining a wider understanding of
feasibility of PRMs systematic assessment. The quantita-
tive and qualitative strands of the research are per-
formed independently, and their results are brought
together in the overall interpretation in order to corrob-
orate and expand our collected data.
Pre-development phase
The aims of this phase are:
 To assess the attitudes of cancer patients and
oncology health care providers towards the routine
use of PRMs in cancer care.
Two focus groups, one with patients and one with
clinicians (physicians, nurses and psychologists) will
be carried out to explore stakeholders needs,
perceptions and attitudes to the use of standardized
PRMs assessment in clinical practice.
A web-survey will be administered to all physicians
(medical, radiation and surgical oncologists as well
as intensive care specialists), nurses and other health
professionals (social workers, physiotherapists and
psychologists) employed at our institution (900 to
1000 people); survey remainders will be sent to non-
responders until a responder rate of at least 50% will
be reached [22]. A sample size of 450 responders
will allow to estimate a two-sided 95% confidence
interval (CI) for the mean of continuous scores with
a precision (half CI width) of 9.2% of its standard
deviation [23]. In case of dichotomus response to
questionnaire items (yes/no), and in the conservative
hypothesis of 50% of “yes”, the precision will be of 4,
6% [23]. The research team will develop an ad hoc
questionnaire investigating which PRMs are used in
clinical practice and in research, and what are the
potential advantages and drawbacks of a systematic
assessment. Potential advantages and drawbacks of
electronic assessment will also be investigated. Data
analysis will be mainly descriptive and stratified by
professional role.
 To identify and analyze electronic assessment
systems developed and used in cancer care.
A systematic review of the medical literature will be
performed in order to find out which systems have
been developed for ePRM assessment in cancer care.
Eligible systems will be defined as those used in
clinical oncology practice settings for any cancer
diagnosys (medical, radiation and surgery oncology
as well as palliative care and psycho-oncology)
which allow the electronic self-assessment of PRMs
and summarize patients’ responses to the clinician.
Papers reporting evidence from any study design
(from feasibility studies to RCT of system
implementation) will be considered eligible. The
search will be carried out on MEDLINE and
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EMBASE using both text search and MeSH terms.
Google Scholar and Scopus in the previous 5 years
will be searched in order to cover a wider set of
potentially relevant sources. A search strategy for
Pubmed is reported in Table 1. Appropriately
revised strategies will be developed for each
database. The index of the main health informatics
journals covering the previous 3 years will be hand
searched. Grey literature (relevant congress
abstracts, web sites and press releases) will also be
examined. Experts in the field will be contacted in
order to identify electronic assessment systems not
yet published in the literature. The review will be
registered on PROSPERO database [24] and its
results will be reported following the PRISMA
guidelines for systematic reviews and meta-analyses
[25].
Electronic systems identified will be compared
exploring the technical feasibility of ePROMs
integration into EMR and identifiyng technological
Fig. 1 Phases of the PATIENT VOICES feasibility project
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barriers and basic system requirements for their
implementation into routine clinical practice. In
addition, functional (ie. configuration dashboard,
data exportability, data visualization, …) as well
as non-functional (ie. integration with other
systems, data storage, …) specifications will be
examined.
Software development and piloting
The objective of this phase is to develop and pilot a
prototype system for electronic collection of PROMs
and PREMs based upon the results of the the pre-
development phase.
The ePRM system is schematically described in Fig. 2.
The whole data management process (patient
Table 1 Search strategy draft to retrieve papers from PubMed
Query number Query content
#15 #1 AND #13 AND #14
#14 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12
#13 #2 OR #3 OR #4 OR #5
#12 Computer [tiab] OR smarphone [tiab] OR web-based OR tablet [tiab]
#11 eHealth [tiab] OR mhealth [tiab] OR E-Health [tiab] OR m-health [tiab]
#10 “Electronic Health Records”[mh]
#9 “Medical Records Systems, Computerized”[mh]
#8 “telemedicine”[mh]
#7 “Medical Informatics”[mh]
#6 “Mobile Applications”[mh]
#5 “patient outcome assessment”[mh] OR “patient outcome assessment”[tiab]
#4 “quality of life”[mh] OR “quality of life”[tiab]
#3 “Patient Reported Experiences”[tiab] OR “Patient Reported Experience”[tiab]
#2 “Patient Reported Outcomes”[tiab] OR “Patient Reported Outcome”[tiab]
#1 cancer [tiab] OR neoplasms [mh] OR tumour [tiab] OR oncol*[tiab] OR carcinoma*[tiab] OR malignan*[tiab]
Fig. 2 Patient Voices system diagram. a and b ePROM and ePREM triggers; c patient questionnaire completion; d feedback to patients; e
individual level feedback to clinicians; f group level feedback clinicians; g administrator tasks. (ePROMs: electronic Patient Reported Outcome
Measurements, ePREMs: electronic Patient Reported Experience Measurements, EMR: Electronic Medical Record)
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registration, questionnaire completion, data elaboration
and clinician consultation) takes place within the hos-
pital network. Expansion of the system allowing also for
data completion by the patient from outside the hospital
network will be developed in the future. Ideally, PRM
triggers will come from hospital acceptance IT systems
(i.e. unified booking centre system (UBCS) and admis-
sion discharge and transfer system (ADT)) (a) or from a
data collection coordinator (b). Then, patients will fill in
PRMs questionnaires through a dedicated interface using
a tablet provided by the hospital (c); data will be elabo-
rated (scoring and graphical presentation) by the system,
and scores will be displayed on the patient interface (d).
All data will be saved into a secure server within the
hospital network.
A distinction must be drawn between ePROMs and
ePREMs as regard how they are reported to clinicians.
While individual ePROMs data will be available to the
clinicians during the consultation, ePREM data collec-
tion should be anonymous to allow the patient freedom
in expressiong judgments; for this reason only group
level reporting will be available for ePREM and then
ePREM system does not need to interact with the EMR.
Figure 2 in fact indicates that after completion, individ-
ual ePROMs scores are real time transferred and graph-
ically displayed into the ePROMs section of the EMR
(e), in order for the clinician to consult them; both
ePROMs and ePREMs will be stored and successively
elaborated for group level reporting accessible to clini-
cians (e). Finally Fig. 2 enlights the role of the “system
administrator” who operates through a dedicated dash-
board to modifiy existing or to add new ePRMs tools, to
authorize users to system access, to download patients
data and manages group level reports (f).
Based on authors previous experiences and on indica-
tions from the literature [17, 26–28], main key features
of the system will be:
– ease of accessibility and usage for the patients and
clinicians
– security of patient data
– linkage to other systems (EMR, appointment/
scheduling, patient portal)
– flexibility (i.e the possibility to create questionnaires
without significant programming effort)
– real-time and user-friendly display of ePROMs
results to clinicians
– meaningful display of PREMs data for monitoring
patient experience with care and for benchmarking
between wards
The prototypes will be pilot tested on 5 clinicians and
10 patient advocates. Comments will be collated on: log-
ging in, accessing the system, navigation through the
questionnaire; accessing and inspection the results. Staff
and patients will be interviewed (semi-structured inter-
views) and changes will be applied to overcome prob-
lems emerged. A new version of the prototype will be
developed and used in the quantitative feasibility phase
described below (Fig. 1). The system will be further re-
fined for improvement during data collection in feasibil-
ity studies. A final version of the system will be
developed at the end of data collection and elaboration.
Feasibility assessment
The aims of this phase are:
 To assess compliance, acceptability, and usability of
a routine ePROMs and ePREMs assessment both by
patients and health care providers.
 To identify patient and health care provider related
barriers.
 To identify potential engagement strategies for the
implementation of routine ePROM assessment in
oncology clinical practice.
Both quantitative (studies A, B and C) and qualitative
(study D) feasibility studies will be carried out:
– STUDY A: a longitudinal study of symptom
screening and monitoring in cancer patients
attending 3 out-patient clinics of INT, namely
palliative care, thoracic oncology and genito-urinary
cancer clinics.
– STUDY B: a cross-sectional study of psychological
distress screening among in-patients admitted to
hematology, medical oncology and breast surgery
wards of INT.
– STUDY C: a longitudinal study for the assessment of
patient experience of care during different phases of
the care process, among patients followed by
multidisciplinary teams in INT, namely the Breast
Cancer Unit, Prostate cancer program, Thoracic
cancer Unit, Head&Neck cancer Unit, Mesenchimal
cancer Unit.
– STUDY D: a feasibility qualitative study (interviews
with patients and focus groups with HCPs) with
users involved in the quantitative studies.
Methods for quantitative feasibility studies
Patient population
All consecutive adult cancer patients attending one of
the above out-patient clinics, in-patient wards or
followed by one of the multidisciplinary team in a pre-
specified time period, will be proposed to be enrolled in
the study. Patients with inability to fill in the system due
to cognitive impairment, psychological disturbances or
language problems as judged by the study personnel
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upon inclusion, will not be eligible. All physicians work-
ing in the outpatient clinic in those days in which system
is tested, are eligible to study participation.
PROMs and PREMs questionnaires
Grounded on their relevance within patient reported
measures literature in oncology [18, 29–32], three PRM
areas have been indentified to be addressed in the three
quantitative feasibility studies: symptom burden (study
A), psychological distress (study B) and patient reported
experience and satisfaction with care received (study C).
Symptom burden will be measured using the Edmon-
ton symptom assessment scale (ESAS) [33] (i.e., pain,
tiredness, drowsiness, nausea, reduced appetite, breath-
lessness, depression, anxiety, well-being) plus sleep, con-
stipation and vomiting. The intensity of each symptom
is assessed on 0–10 numerical rating scales (higher
scores indicate greater symptom severity). The ESAS
instrument is one of the most widely used and with a ro-
bust psychometric documentation in various languages
[33, 34] and has been validated in Italian in a sample of
advanced cancer patients [35].
Psychological distress screening among in-patients will
be performed using the Distress Thermometer (DT), a
single-item 0–10 numerical rating scale, on which par-
ticipants rate their level of distress from any cause in the
preceding 7 days [36]. The DT is accompanied by a 35
item problem list, which prompts patients to identify
their problems in five different categories: practical, fam-
ily related, emotional, spiritual/religious, and physical.
Scores of 4 or higher suggest a level of distress that has
clinical significance. The DT has been validated in
Italian language [37].
In the longitudinal feasibility pilot study C, question-
naires for the survey will be developed from existing in-
struments (the questionnaire developed in Bench-Can
and EURACAN projects [38], the patient satisfaction
with cancer care questionnaire [39] and the institutional
customer satisfaction survey). The adaptation of the
questionnaire content to the specific patient population,
will be performed with the contribution of clinicians of
the multidisciplinary teams involved, discussed with
cancer patients’ representatives and pre-tested among a
restricted group of users.
Data collection procedures
A trained data collection coordinator (DCC), a research
nurse or a psychologist or a physician, will perform eligi-
bility screening, propose the patient to be enrolled in the
study, collect written informed consent and provide
basic training in how to use the device. The DCC will
also be available for any help the patient may need
during the compilation. At the end of the compilation,
system usability as perceived by patient will be collected
and the following data will be registered by the DCC:
reason for potential incompleteness, amount of assist-
ance needed and system usability. The system will
automatically register clinician access to patients’ data.
System usability as perceived by clinicians will be
collected at the end of study period.
Patients attending the out-patient clinics involved in
Study A, will fill in the symptom burden questionnaire
at the first 3 visit performed during the study period,
while symptom distress screening among in-patients
(Study B) will be performed on admission.
In Study C questionnaires will be filled-in along the
care pathway at the following clinically relevant points:
T0 (at diagnosis), T1 (first treatment decision making
step), T2 (end of active treatment), T3 (disease progres-
sion), T4 (follow-up). Exact timing of T0 to T4 will be
different for the five multidisciplinary team Units
involved and the maximum follow-up time will not
exceed 6 months from enrollment.
Study endpoints
The main study endpoints are the rates of compliance
with the system at baseline assessment by both patient
(percent of eligible patients completing electronic ques-
tionnaires) and physicians (percent of clinical encounters
in which the physician gets access to data provided by
ePROM) (the latter only in studies A and B).
Secondary endpoints are:
– proportion of eligible patients among those
screened;
– proportion of patients refusing to use the system
and reasons for refusal;
– proportion of patients filling in the system without
external help;
– average proportion of missing items for each
compilation;
– average time to fill in the system;
– average level of perceived system usability by
patients;
– average level of perceived system usability by
physicians;
– identification of features of the system which need
refinement.
Additional secondary endpoints in the longitudinal
feasibility studies:
– rate of drop-out during the longitudinal assessment
and reasons for drop-out;
– rate of intermittent missing assessment and reasons
for missingness;
– clinician perception about the usefulness of PROMs
for treatment decisions.
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Assessment methods
A paper and pencil self-report form will be used to
gather patients’ education level and acquaintance/experi-
ence with e-devices (smartphones, tablets, computers).
Patients’ basic demographic and clinical data (sex, date
of birth, tumor site, stage of the disease, pain and other
symptom medication prescription) will be gathered from
the EMR. Time needed to complete data collection for
each patient will be registered by the system. Data re-
garding gender, years of experience in oncology practice
and experience with e-devices, will be collected also for
the clinicians participating in the study. After testing, pa-
tients and clinicians will fill out the System Usability
Scale (SUS), a standardized questionnaire used to assess
participants’ perceptions of system usability [29]. The
SUS is made up of 10 items rated on a 5-point Likert
scale and its final score is a summated rating scale
ranging from 0 to 100 after resacaling. An open ended
question will also be asked to all participants in order to
assess whether any of the system features were difficulty
to use or for which they propose modifications.
Sample size and data analysis
Six hundred consecutive cancer patients will be enrolled
(200 in each of studies A, B, and C).
In the hypothesis that the percentage of successful
assessments/consultation (“rate of compliance” among
patients and clinicians) is 50% (hypothesis of maximum
variability, and then maximum imprecision), a sample
size of 200 allows the estimation of a 95% CI for the rate
of compliance with a precision (half width) of 6.9% [23].
Basic descriptive statistics will be applied to
characterize the study sample. Point and interval
estimates (95% CI) of rates and averages described in
primary and secondary endpoints, will be calculated for
the whole sample and by outpatient clinic/inhospital
ward. The association between patient related character-
istics and binary as well as continuous outcomes will be
respectively analyzed with logistic and linear regression
models.
Methods of qualitative feasibility study
The use of qualitative techniques, namely semi-
structured face-to-face interviews and focus groups, is
addressed to explore attitudes and opinions about PRMs
and ePRMs of both patients and HCPs in the pre-
implementation phase, to identify patient and clinician
related barriers to adopt ePRM data collection in oncol-
ogy clinical practice during the feasibility assessment
phase (Fig. 1), as well as to pinpoint engagement strat-
egies to promote the use of ePRM system in routine
care.
Two separate focus groups (10 patients and 10 clini-
cians) will be carried out during the pre-development
phase of the ePROM system. We opted for two separate
focus groups to compare the viewpoints of patients and
clinical professionals. After the ePROM feasibility phase,
three focus groups, one for each study A, B and C (10
participants each), will also be carried out among clini-
cians (physicians, psychologists, nurses) who have partic-
ipated in the three studies. The number of cases in focus
groups was determined to support the depth of case-
oriented analysis that is fundamental to this mode of
inquiry and that would not be possible with wider sam-
ple sizes [40], to ensure sufficient heterogeneity between
the characteristics of the participants and to allow every-
one to intervene in the discussion, avoiding potential
frustration due to lack of time to express one’s point of
view and opinion [41]. The recruitment strategies will be
addressed to ensure heterogeneity with respect to stage
of disease (only for patients), professional profiles (only
for clinicians) and gender (for both). Thirty semi-
structured interviews (enrolling 10 patients for each of
study A, B and C) will also be carried out. Purposive
sampling will be performed in order to cover a wide
range of patient characteristics (sex, age, disease site and
stage as well as experience with e-devices and study par-
ticipation). Feasibility issues addressed during inter-
views/focus groups will cover aspects common to each
study (ease of use of the ePRM, relevance of the content,
suggestions for improvement) as well as disease/setting
related aspects. A special attention will be dedicated to
elderly and to patients with low experience with
electronic devices.
Experts in qualitative methods will be engaged both
for training and supervision of interviewers that will be
enrolled among volunteers and trainees at INT. Data
collected will be analysed through T-Lab, a linguistic,
statistical and graphical software designed to allow text
analysis of qualitative data.
Post-development phase
The aim of this phase is twofold: to identify specific
questionnaires and to develop strategies for the imple-
mentation of ePRM systematic assessment in routine
oncology care at our Institute (Fig. 1).
A variety of questionnaires are available for the assess-
ment symptom burden, psychological distress, side ef-
fects of cancer treatment, experience with care received
and quality of life. The choice is to be based on aim of
assessment, feasibility and possibility of intervention
after assessment. A consensus meeting will be carried
out after the feasibility phase is concluded to decide
upon which tools to use during the future implementa-
tion phase of the PATIENT VOICES project. Represen-
tatives of all the clinical and research wards of the INT
as well as the research personnel involved in the present
project will be invited to participate in the consensus.
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Like any change in clinical processes, successful imple-
mentation of electronic patient reported assessment in
routine clinical workflow, requires institutional commit-
ment from leadership, buy-in from administrators as
well as the involvement of multiple stakeholders along
the development process. For this reason a multi-
disciplinary stakeholder team (MDST) including
researchers, oncology clinicians, health informatics pro-
fessionals, health system administrators and patients will
be involved in the development of potentially effective
implementation strategies.
The MDST will examine evidence from the literature,
results of the survey and of the feasibility studies to an-
swer the following questions:
a) How, where, and with what frequency will ePRMs
be administered?
b) How can users be trained and engaged?
c) How will the ePROM-EMR system interaction be
governed?
d) How will ePROM and ePREM data be acted upon?
e) What are the ethical and legal implications of the
systematic assessment?
Discussion and consensus among MDST members on
the topics above, will be achieved via both meeting
participation and written document circulation.
Data protection issues
Confidentiality issues regarding the registration, hand-
ling and storage of data will be a major concern during
the system development process. Solution will adhere to
current national and European data protection regula-
tions, in particular in accordance with Regulation (EU)
2016/679 of 27 April 2016 (General Data Protection
Regulation). Data communication between the device
used for data entry and the storage server will be
secured using HTTPS over SSL. Appropriate authentica-
tion systems will ensure verification of the user identity.
Coded PROMs data collected by electronic devices will
be transferred to and stored on secure servers hosted by
INT. Data will be pseudonimized and encrypted, access
logs registered and managed in compliance with GDPR.
Patient usernames (codes) that will be used for linking
these data to patient’s individual EMR, will also be
imported separately and stored into a database on secure
servers hosted by INT.
Discussion
Despite the moral imperative to assess and address to
the issues that matter to people with cancer as part of
their routine clinical care, PRMs are not commonly used
in clinical practice in oncology and awareness of their
clinical usefulness is lacking both among HCPs and
patients. Admistering and filling in PRMs questionnaire
is often considered as “paper work”, feedback about self-
assessments are normally not provided to patients, and
patients themselves often do not expect to receive any.
On these bases it is difficult that PRMs can be usefully
implemented as clinical tools, despite recent evidences
of their positive impact on patient care [9–12].
A number of initiatives/projects have been proposed
to promote systematic assessment of PRMs in clinical
practice. The innovation of the PATIENT VOICES pro-
ject lays in redefining organizational procedures for the
administration of PRMs tools in clinical practice, based
on the methodological experience from PRMs imple-
mentation in research, on the use of IT technology and
on a wide engagement of patients, clinicians, researchers
and health system administrators for the definition of
new procedures. PRM implementation in clinical
practice is in fact a complex intervention, which requires
change in behaviours in all stakeholders involved and
this is the reason why the project puts such emphasis in
studying feasibility and developing implementation
strategies finalized to overcome potential barriers at
various levels [42].
The PATENT VOICES project is extensively based on
the use of electronic devices, in line with the present
trend in clinical cancer care. The challenge is to develop
technologies aimed at overcoming barriers of paper and
pencil format (i.e. difficulties in calculating scores, in
showing time trends, in interpreting single patient scores
with respect to normative data) meanwhile truly inte-
grated with existing IT tools used in everyday clinical
practice, the EMR first among others. Additionally, only
electronic assessment of PRMs and their effective inte-
gration within the EMR will allow patients’ perspectives
to be fully included in the “big data roadmap” [43], a
revolution in health care which is about to happen with-
out the contribution of the most important stakeholder:
the patient.
Improvement in communication is an expected final
result of the PATIENT VOICES project. In addition to
the possibility for the patients to express subjective
evaluation regarding their condition and experience of
care, the use of common platforms and/or PRMs agreed
upon by different care providers may also favour com-
munication among clinicians and promote multidiscip-
linary approach to patient care. However, PRM scores
are difficult to communicate in themselves, reflecting
the fact that they were developed to report “group level”
information in reaserch, rather than individual data in
clinical practice. Whereas scores from symptom inven-
tories (i.e. ESAS) are fairly self evident and their commu-
nication maybe easy (i.e “Dear Mr. Brown your pain
intensity has changed from 7 to 4 (0-10 NRS) after 1
week analgesic treatment”), the communication of
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composite scale scores, like for example psychological
status questionnaires or multidimensional quality of life
scales, is more complex and guidelines are missing. For
this reason a consistent part of this feasibility project, in
particular software development, is dedicated to the
study of how PRM scores are reported to stakeholders
(clinicians and patients primarily).
For this feasibility study we chose the adoption of a
mixed methods research design which will allow to
expand and strengthen our study’s conclusions through
enrichment of the analysis and findings and the recipro-
cal validation of data from the two different research
frameworks (Creswell & Plano Clark 2007).
This is a single centre project carried out in a compre-
hensive cancer centre and this may impact on results
generalizability. However reports of real-world PRO
implementation are limited [44] and to the best of our
knowledge this is the first project specifically designed to
address implementation barriers and strategies for the
systematic assessment of PRMs in cancer care in Italy.
The PATIENT VOICES is an innovative project and
as such it may fail to achieve expected impact on the
side of technology (i.e. do not reach a full integration of
the ePRMs with EMR) or on the side of clinical practice
application (i.e. do not reach expected levels of engage-
ment engagement by clinicians and compliance by pa-
tients, mainly elderly people or those less educated/less
familiar with electronic devices). Nevertheless, the docu-
mentation of implementation barriers achieved within
the feasibility phase and the development of implemen-
tation strategies by the MDST will serve as a starting
point for future and more focused interventions aimed
at achieving effective ePRMs routine assessment in
cancer care and constitute a potential paradigm shift in
the management of clinical patient relationships.
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Box 1
The PATIENT VOICES project has been developed at the
Fondazione IRCCS Istituto Nazional dei Tumori- Milano, a
comprehensive cancer centre pioneer in the reaserch field of
quality of life in oncology. This was possible also thanks to the
scientific contribution of Dott. Marcello Tamburini, former
director of the Clinical Psychology Unit as well as founder and
first Editor in chief of Health and Quality of Life Outcomes
journal.
Marcello strongly believed in the value of patient reported
outcome and experience measures for clinical practice in cancer
care, and had fully understood the potential of information and
communication technology far a long ago. In 2001 he wrote “A
standardised method of evaluating quality of life can help us to
understand patient problems to the same degree as standard
biological assessments do. This could provide an easy way to
anticipate the main problems of the patient. Its function could be
similar to that of a thermometer, which detects fever without
revealing its cause, the identification of which is the physician’s
task. The development of questionnaires in electronic format could
help support the clinical use of HRQOL questionnaires, in particular
through the use of HTML or similar format with an automatic
scoring, a data-entry database and a graphic presentation of the
scores. Quality-of-life data could be also used to improve the com-
munication between doctor and patient in order to elicit the pa-
tient’s preferences concerning anticancer and symptom therapies.”
[45]
This project is dedicated to his memory (1948–2007).
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